2026-05-05

# Quantum Intelligence — Daily, 2026-05-05

IBM, Cleveland Clinic and RIKEN reported same-day a quantum simulation of a 12,635-atom trypsin protein on IBM Quantum Heron processors paired with the Fugaku and Miyabi-G classical supercomputers. The result is the largest known biological simulation executed on a quantum computer and a 40× scale advance over the same partnership's six-month-old Trp-cage benchmark. Two late-discovered same-week corporate items at tracked public quantum names round out the brief: D-Wave's CEO compensation amendment via 8-K Item 5.02 and IonQ's commercial Earth-observation product launch on its Capella Acadia satellite constellation.

## Lead

### IBM, Cleveland Clinic and RIKEN simulate a 12,635-atom protein on IBM Quantum Heron — the largest known biological simulation on a quantum computer

According to IBM's 2026-05-05 Quantum blog post and the same-day PR Newswire distribution issued jointly with Cleveland Clinic and RIKEN, the partnership simulated the 12,635-atom trypsin protein complex using IBM's quantum-centric supercomputing approach. Per the supporting arXiv preprint at arxiv.org/abs/2605.01138, two 156-qubit IBM Quantum Heron processors — one at Cleveland Clinic in Cleveland, Ohio and one at RIKEN in Wakō, Japan — were paired with the Fugaku supercomputer at RIKEN and the Miyabi-G supercomputer (jointly operated by the University of Tokyo and the University of Tsukuba) to compute electronic-structure fragments of the protein.

Per IBM's reporting, the largest fragment subproblem used up to 94 qubits and approximately 6,000 quantum operations. IBM and partners introduced EWF-TrimSQD, a quantum-classical hybrid algorithm that, the team reports, reduced overhead and enabled simulations roughly 40 times larger in molecular size than the Trp-cage milestone the same partnership reported six months earlier. The team also reports an approximately 210× per-step accuracy improvement in a key embedding step over the same period.

The score-6 anchoring matches the rubric's "credible benchmark result with industry-wide implications" band. The result is reproducible against published metrics; the algorithmic claim has an arXiv preprint anchor; and the same workflow can in principle be re-run by IBM cloud customers running on Heron-class hardware. The score is held below 7 because the demonstration is hybrid quantum-classical (classical supercomputers carry the decomposition and reassembly steps; quantum hardware handles the quantum-mechanical-behavior fragments), the preprint is not peer-reviewed yet, and a 94-qubit usage on a 156-qubit processor with 6,000 operations sits well inside the noisy-intermediate-scale regime — there is no claim of fault-tolerant operation.

The result is the strongest 2026-to-date data point in the quantum-for-biology arc: it follows the 2026-03-26 IBM materials-properties demonstration (score 6), the 2026-04-16 IBM genome-loading research demo (score 5), the 2026-04-16 Wellcome Leap $50M Quantum for Bio challenge program (score 7), and the 2026-04-22 IBM Q1 2026 quantum-roadmap reaffirmation (score 6). It also positions IBM heading into Krishna's IBM Think 2026 keynote later today (12:30 UTC), where the quantum-advantage progress section is pre-trailed in the 2026-05-04 IBM Newsroom media alert.

For the broader public-quantum equity universe the read is more nuanced: the result raises the bar for what "industry-relevant scale" means in molecular simulation and pressures pure-play hardware vendors (IonQ, Rigetti, D-Wave, Pasqal, Atom Computing, Quantinuum) to publish comparable scale claims against named molecules and named classical baselines rather than abstract benchmark suites. The Quantinuum IPO thread sits adjacent — a comparable trapped-ion biological-simulation milestone from Quantinuum would be a meaningful pre-IPO marketing data point.

## Late-surfaced developments (within the trailing-10-day Step 7b window)

### On 2026-05-04, D-Wave Quantum filed an 8-K (Item 5.02) disclosing a Third Amendment to CEO Alan Baratz's employment agreement with a $13.488M RSU grant and a $700,000 base salary

Per D-Wave Quantum's 2026-05-04 8-K filing on SEC EDGAR (accession 0001907982-26-000049), the Third Amendment to the Amended and Restated Employment Agreement with President and CEO Dr. Alan Baratz takes effect 2026-04-30. The amendment increases Baratz's annual base salary to $700,000 retroactive to 2026-01-01 and grants restricted stock units with an aggregate value of $13,488,000 under D-Wave's 2022 Equity Incentive Plan. The board's compensation committee recommended the amendment.

This is CEO retention via equity rather than a CEO transition. It maps to the score-5 "Notable, worth logging" band. The catalyst-adjacent timing — D-Wave's Q1 2026 earnings is scheduled for 2026-05-12 before market open, eight calendar days from the filing — is noted but does not trigger insider Pattern D escalation, which applies to insider transactions (Patterns A/B/C/E), not to compensation-amendment filings.

The combined picture going into Q1 earnings: locked-in management; the prior 2026-04-22 Sophie C. Ames VP discretionary sale ($65,544 single-insider, sub-Pattern-A); and the 2026-04-29 D-Wave Investor Day announcement scheduled 2026-06-01 at NYSE per the prior EDGAR scan. The RSU grant's vesting schedule is not disclosed in the headline filing; whether the vest is time-based or tied to revenue/technical milestones will be visible in the Q1 10-Q. Subsequent Form 4 grant-receipt withholding sales by Baratz are also a near-term watch.

### On 2026-05-04, IonQ launched a commercial InSAR Earth-monitoring service running on its Capella Acadia SAR constellation (non-quantum core)

Per IonQ's 2026-05-04 investor-relations release and BusinessWire distribution, IonQ launched a commercial Interferometric Synthetic Aperture Radar (InSAR) Earth-monitoring product line. The offering claims millimeter-precision ground-deformation detection on a three-day revisit cycle using IonQ's eight-satellite Capella Acadia radar constellation in mid-inclination and sun-synchronous orbits, positioned as an automated tasking-and-delivery service for infrastructure, energy, insurance, urban-development, and national-security customers.

No first customers, dollar values, or first-pilot timelines were disclosed. The technology stack is classical SAR phase-difference processing on the Capella platform; the announcement contains no quantum sensor, quantum processing, or quantum-networking component. This is a minor product-line extension at a tracked pure-play public quantum company, mapping to the §8.2 score-4 "Minor product-line extension" band, and is logged for completeness rather than for newsletter signal — the score 4 is held flat with the "non-quantum-core" tag.

The launch validates one of the operating arguments for IonQ's prior Capella Space acquisition: that the SAR constellation can carry standalone commercial revenue while IonQ's core quantum-networking architecture matures. Watch for whether the InSAR product line is reported as a separable revenue segment in IonQ's Q1 2026 earnings 2026-05-06.

## What's quiet today

- **Insider activity.** EODHD's incremental insider-transaction fetch from cursor 2026-04-28 to 2026-05-05 across 19 tracked U.S. tickers returned zero new rows. The cursor remains at 2026-04-28; no new appends to /signals/insider/. The 14-day insider window now holds two single-insider records — the SealSQ O'Hara CFO sales (2 transactions, ~$45.9K) and the Coherent Corp Luther CFO sale ($702K). Both fail the Pattern A ≥3-distinct-insider trigger; the prior-window D-Wave Ames VP record (2026-04-20, $65.5K) has aged out of the 14-day window. Zero patterns promoted; open_insider_patterns remains empty.
- **Earnings calendar.** EODHD surfaced one calendar-forward row: Coherent Corp (COHR.US) reports Q3 FY26 on 2026-05-06 AfterMarket against an estimate of $1.39 EPS. Actual is not yet populated — watch the next run. IonQ Q1 2026 reports the same day after market close.
- **Corporate actions beyond D-Wave's 5.02.** No splits, dividends, shelf offerings, or other 8-Ks on tracked U.S. tickers in the 2026-05-01 through 2026-05-05 window beyond items already classified. The Coherent Corp 5.02 (CSO Barbarossa retirement, filed 2026-04-28) was deferred to the W18 weekly per the scheduled-run-4 catch-up rule; it is not reopened in today's wrapper.
- **IBM Think 2026 keynote.** Krishna's keynote begins 12:30 UTC on 2026-05-05, after this run's close. Any same-day announcements from the keynote will surface in the 2026-05-06 daily run.

## Sources

**IBM × Cleveland Clinic × RIKEN 12,635-atom trypsin protein simulation (2026-05-05):**
- PR Newswire (joint distribution) — "Cleveland Clinic, RIKEN, and IBM Model a 12,635-Atom Protein — the Largest Known to Be Simulated with Quantum Computers." https://www.prnewswire.com/news-releases/cleveland-clinic-riken-and-ibm-model-a-12-635-atom-protein--the-largest-known-to-be-simulated-with-quantum-computers-302762057.html
- arXiv preprint — Per IBM's announcement, the supporting preprint is at https://arxiv.org/abs/2605.01138
- IBM Quantum Blog — "Cleveland Clinic and IBM debut new quantum simulation workflow." https://www.ibm.com/quantum/blog/cleveland-clinic-protein-qcsc
- The Quantum Insider — earlier coverage of the IBM × Cleveland Clinic protein workflow (2026-03-27). https://thequantuminsider.com/2026/03/27/cleveland-clinic-ibm-debut-quantum-workflow-proteins/
- Quantum Computing Report — "Cleveland Clinic and IBM Implement Quantum Workflow for Protein Simulation." https://quantumcomputingreport.com/cleveland-clinic-and-ibm-implement-quantum-workflow-for-protein-simulation/
- HPCwire — "Cleveland Clinic and IBM Debut New Quantum Workflow for Simulating Proteins." https://www.hpcwire.com/off-the-wire/cleveland-clinic-and-ibm-debut-new-quantum-workflow-for-simulating-proteins/

**D-Wave Quantum CEO Baratz employment agreement amendment (2026-05-04):**
- SEC EDGAR — D-Wave Quantum 8-K Items 5.02 + 9.01, accession 0001907982-26-000049. https://www.sec.gov/Archives/edgar/data/1907982/000190798226000049/0001907982-26-000049-index.htm
- StockTitan — "D-Wave Quantum boosts CEO pay and RSU grant" (8-K filing summary). https://www.stocktitan.net/sec-filings/QBTS/8-k-d-wave-quantum-inc-reports-material-event-98f80cdfd24d.html

**IonQ commercial InSAR product launch (2026-05-04):**
- IonQ — "Automated 3-Day InSAR Monitoring: Precision Ground Deformation." https://www.ionq.com/news/ionq-launches-commercial-insar-capability-enabling-automated-millimeter-scale-earth-monitoring
- Business Wire — "IonQ Launches Commercial InSAR Capability, Enabling Automated, Millimeter-Scale Earth Monitoring." https://www.businesswire.com/news/home/20260504322186/en/IonQ-Launches-Commercial-InSAR-Capability-Enabling-Automated-Millimeter-Scale-Earth-Monitoring
- The Quantum Insider — "IonQ Introduces InSAR Monitoring Capability for Earth Observation." https://thequantuminsider.com/2026/05/04/ionq-insar-earth-monitoring-launch/
- SpaceNews — "IonQ to offer ground-movement monitoring via Capella radar satellites." https://spacenews.com/ionq-to-offer-ground-movement-monitoring-via-capella-radar-satellites/

---

*Generated 2026-05-05. Schema v2.3. Three events; one passed the score-6 publication threshold and triggered today's daily newsletter. Two late-discovered (within trailing-10-day Step 7b window) corporate-action items at tracked public quantum names included for completeness.*